Abdalla A, Mazur N A, Fofanova T V
Kardiologiia. 1989 Jul;29(7):29-32.
Allapinine (Class IC), a new antiarrhythmic agent, was studied in 76 patients with premature contraction. Allapinine was found to be beneficial both in ventricular and supraventricular premature beats. Oral allapinine usually showed its effect 40-60 minutes following its administration, its maximum action being 4-5 hours later, its duration was some 8 hours. The optimal dose of the drug amounted to 75 mg/day. Larger-dose allapinine produced adverse effects, its lower dosage had no antiarrhythmic effect. The drug failed to affect blood pressure, heart rate, QT interval length. The PQ interval and QRS complex were increased. The side effects were dose-dependent. There was a risk of the drug's arrhythmogenic effect.
新型抗心律失常药物阿拉平宁（IC类）在76例早搏患者中进行了研究。发现阿拉平宁对室性和室上性早搏均有益。口服阿拉平宁通常在给药后40 - 60分钟起效，最大作用在4 - 5小时后出现，持续时间约为8小时。该药的最佳剂量为75毫克/天。较大剂量的阿拉平宁会产生不良反应，较低剂量则无抗心律失常作用。该药对血压、心率、QT间期长度无影响。PQ间期和QRS波群增宽。副作用呈剂量依赖性。该药存在致心律失常作用的风险。
